Cargando…

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group

BACKGROUND: Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adler, Sabine, Huscher, Dörte, Siegert, Elise, Allanore, Yannick, Czirják, László, DelGaldo, Francesco, Denton, Christopher P., Distler, Oliver, Frerix, Marc, Matucci-Cerinic, Marco, Mueller-Ladner, Ulf, Tarner, Ingo-Helmut, Valentini, Gabriele, Walker, Ulrich A., Villiger, Peter M., Riemekasten, Gabriela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791165/ https://www.ncbi.nlm.nih.gov/pubmed/29382380 http://dx.doi.org/10.1186/s13075-018-1517-z

Ejemplares similares

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
por: Blagojevic, J., et al.
Publicado: (2019)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
por: Bütikofer, Lukas, et al.
Publicado: (2020)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population
por: Hachulla, Eric, et al.
Publicado: (2015)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database
por: Allanore, Yannick, et al.
Publicado: (2020)

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
por: Jaeger, Veronika K., et al.
Publicado: (2016)

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study
por: Ndosi, Mwidimi, et al.
Publicado: (2018)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort
por: Allanore, Yannick, et al.
Publicado: (2016)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Interstitial pneumonia with autoimmune features: a new classification still on the move
por: Cavagna, Lorenzo, et al.
Publicado: (2018)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China
por: Hu, Shasha, et al.
Publicado: (2018)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis
por: MARCH, Christine, et al.
Publicado: (2020)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario
por: Miniati, Irene, et al.
Publicado: (2009)

Novel tools for molecular analysis in synovium
por: Mueller-Ladner, U, et al.
Publicado: (2003)

Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review
por: Wang, YuKai, et al.
Publicado: (2017)

HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc
por: Distler, O, et al.
Publicado: (2002)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Volumetric Cone Beam Computed Tomography for the Assessment of Oral Manifestations in Systemic Sclerosis: Data from an EUSTAR Cohort
por: Iordache, Cristina, et al.
Publicado: (2019)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis
por: Allanore, Yannick, et al.
Publicado: (2011)

Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome
por: Lazzeri, Chiara, et al.
Publicado: (2021)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population
por: Borie, Raphael, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jp2ndpv9sv95p1pqlscva4sqf6